"Eli Lilly reports positive data from trial of Omvoh for Crohn’s disease" was originally created and published by Clinical ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation. 2,3 "Many ...

Eli Lilly and Co.’s approval for Omvoh to treat moderate to severe Crohn’s disease in adults marks the Indianapolis company’s growing presence in the treatment of inflammatory bowel disease.

Omvoh has possible interactions with certain vaccines. Examples include the chickenpox vaccine and the nasal spray flu vaccine (FluMist). Talk with your doctor to avoid potentially harmful effects ...

Omvoh (mirikizumab-mrkz) has potential interactions with certain vaccines and health conditions. These interactions could cause harmful effects in some people. Omvoh is used in adults to treat ...

SAN FRANCISCO — Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 weeks of Omvoh therapy maintained those results through ...

Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19, which is a key contributor to intestinal inflammation. Participants ...

Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS, Feb. 7, 2025 /PRNewswire/ -- Eli ...